Background Ovarian cancer has the highest mortality rate among gynaecological malignancies and is initially screened using ultrasound. Owing to the high complexity of ultrasound images of ovarian masses and the anatomical characteristics of the deep pelvic cavity, subjective assessment requires extensive experience and skill. Therefore, detecting the ovaries and ovarian masses and diagnose ovarian cancer are challenging. In the present study, we aimed to develop an automated deep learning framework, the Ovarian Multi-Task Attention Network (OvaMTA), for ovary and ovarian mass detection, segmentation, and classification, as well as further diagnosis of ovarian masses based on ultrasound screening. Methods Between June 2020 and May 2022, the OvaMTA model was trained, validated and tested on a training and validation cohort including 6938 images and an internal testing cohort including 1584 images which were recruited from 21 hospitals involving women who underwent ultrasound examinations for ovarian masses. Subsequently, we recruited two external test cohorts from another two hospitals. We obtained 1896 images between February 2024 and April 2024 as image-based external test dataset, and further obtained 159 videos for the video-based external test dataset between April 2024 and May 2024. We developed an artificial intelligence (AI) system (termed OvaMTA) to diagnose ovarian masses using ultrasound screening. It includes two models: an entire image-based segmentation model, OvaMTA-Seg, for ovary detection and a diagnosis model, OvaMTA-Diagnosis, for predicting the pathological type of ovarian mass using image patches cropped by OvaMTA-Seg. The performance of the system was evaluated in one internal and two external validation cohorts, and compared with doctors' assessments in real-world testing. We recruited eight physicians to assess the real-world data. The value of the system in assisting doctors with diagnosis was also evaluated. Findings In terms of segmentation, OvaMTA-Seg achieved an average Dice score of 0.887 on the internal test set and 0.819 on the image-based external test set. OvaMTA-Seg also performed well in ovarian mass detection from test images, including healthy ovaries and masses (internal test area under the curve [AUC]: 0.970; external test AUC: 0.877). In terms of classification diagnosis prediction, OvaMTA-Diagnosis demonstrated high performance on image-based internal (AUC: 0.941) and external test sets (AUC: 0.941). In video-based external testing, OvaMTA recognised 159 videos with ovarian masses with AUC of 0.911, and is comparable to the performance of senior radiologists (ACC: 86.2 vs. 88.1, p = 0.50; SEN: 81.8 vs. 88.6, p = 0.16; SPE: 89.2 vs. 87.6, p = 0.68). There was a significant improvement in junior and intermediate radiologists who were assisted by AI compared to those who were not assisted by AI (ACC: 80.8 vs. 75.3, p = 0.00015; SEN: 79.5 vs. 74.6, p = 0.029; SPE: 81.7 vs. 75.8, p = 0.0032). General practitioners assisted by AI achieved an average performance of radiologists (ACC: 82.7 vs. 81.8, p = 0.80; SEN: 84.8 vs. 82.6, p = 0.72; SPE: 81.2 vs. 81.2, p > 0.99). Interpretation The OvaMTA system based on ultrasound imaging is a simple and practical auxiliary tool for screening for ovarian cancer, with a diagnostic performance comparable to that of senior radiologists. This provides a potential tool for screening ovarian cancer. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).

RCC is a malignant tumor arising from the urothelium of renal parenchyma that remains challenging to be treated. In this study, we assessed the anti-tumor effects of Resveratrol liposomes (RES-lips) combined with sorafenib on renal cell carcinoma (RCC) and explored the potential mechanisms underlying the improvement of sorafenib resistance models. Tumor growth and survival following treatment with sorafenib alone or in combination with RES-lips was evaluated in a RCC xenograft mouse model. Flow cytometry results demonstrated that the combination of RES-lips and sorafenib significantly enhanced the G1/S phase arrest of sorafenib-resistant cells. When compared with the PBS or monotherapy groups, treatment with RES-lips combined with sorafenib exhibited significant inhibition of tumor growth in the RCC xenograft mouse model with tumor growth inhibition (TGI) rates and complete remission (CR) rates of 90.1 % and 50 %, respectively. Concersely, the maximum TGI rate was 53.6 % in the RES-lips monoherapy group and 29.2 % and in the sorafenib monotherapy group, and no animals achieved CR. Additionally, the current combination therapy promoted the proliferation of unactivated splenic lymphocytes and the proliferation of soybean protein A- and lipopolysaccharide-stimulated lymphocytes compared with PBS or monotherapy treatments. Further western blotting analysis suggested that RES-lips may enhance the resistance of RCC to sorafenib by inhibiting PI3K-AKT-mTOR and VHL-HIF signaling pathways, ultimately augmenting the tumor growth inhibition effect of the combination therapy. RES-lips may improve the sorafenib resistance in RCC, and the underlying mechanism may be related to the regulation of PI3K-AKT-mTOR and VHL-HIF signaling pathways.

Drug local delivery system that directly supply anti-cancer drugs to the tumor microenvironment (TME) results in excellent tumor control and minimizes side effects associated with the anti-cancer drugs. Immune checkpoint inhibitors (ICIs) have been the mainstay of cancer immunotherapy. However, the systemic administration of ICIs is accompanied by considerable immunotherapy-related toxicity. To explore whether an anti-PD-L1 antibody administered locally via a sustained-release gel-forming carrier retains its effective anticancer function while causing fewer colitis-like side effects, CT, a previously reported depot system, was used to locally deliver an anti-PD-L1 antibody together with curcumin to the TME in bladder cancer-bearing ulcerative colitis model mice. We showed that CT-mediated intratumoral coinjection of an anti-PD-L1 antibody and curcumin enabled sustained release of both the loaded anti-PD-L1 antibody and curcumin, which contributed to substantial anticancer effects with negligible side effects on the colons of the UC model mice. However, although the anti-PD-L1 antibody administered systemically synergized with the CT-mediated intratumoral delivery of curcumin in inhibiting tumour growth, colitis was significantly worsened by intraperitoneal administration of anti-PD-L1 antibody. These findings suggested that CT is a promising agent for the local delivery of anticancer drugs, as it can allow effective anticancer functions to be retained while sharply reducing the adverse side effects associated with the systemic administration of these drugs.

To investigate the associations of GCKR and ADIPOQ variants with the risk of gestational diabetes mellitus (GDM) in Chinese women. GCKR rs1260326, ADIPOQ rs266729, and rs1501299 were selected and genotyped in 519 GDM patients and 498 controls. Candidate SNPs were genotyped using multiplex polymerase chain reaction (PCR) combined with next-generation sequencing methods, and the association of these SNPs with GDM was analyzed. We found that GCKR rs1260326 was significantly associated with an increased risk of GDM in the allele model, the codominant model (CC vs. TT), the dominant model, the recessive model, and the genotypic model distributions (p = 0.0029, p = 0.0022, p = 0.0402, p = 0.0038, and p = 0.0028, respectively). The rs1260326 polymorphism was shown to be associated with 1 h-OGTT level and gravidity in GDM patients (CC vs. TT: p = 0.0475 and p = 0.0220, respectively). Diastolic blood pressure (DBP) was significantly higher in the GDM patients with the rs266729 GG genotype compared to those with the CC or CG genotype (p = 0.0444 and p = 0.0339, respectively). The DBP of the GDM patients with the rs1501299 GT genotype was lower than that of those with the GG genotype (p = 0.0197). There was a weak linkage disequilibrium value between the GCKR and ADIPOQ SNPs. The genes GCKR and ADIPOQ may be involved in the pathophysiology of GDM.

Objective:To assess the clinical value of double-plane transrectal ultrasonography (DPTRUS) in the diagnosis and treatment of pelvic diseases.Methods:A retrospective analysis was performed on patients with pelvic diseases treated at Zhejiang Provincial People's Hospital from August 2022 to March 2023. The pelvic diseases were diagnosed by routine ultrasound (RUS), contrast-enhanced ultrasound (CEUS), and high-frequency ultrasound guided puncture biopsy or catheter drainage using a bi-planar transrectal probe (convex and linear array), including ultrasonic diagnosis and puncture biopsy of 173 cases of prostate disease, 4 cases of pararectal mass, and 1 case of cervical cancer, and ultrasonic diagnosis and catheter drainage of 1 case of encapsulated effusion in the uterine rectal fossa and 1 case of prostatic abscess. The accuracy, sensitivity, and specificity of RUS and CEUS in DPTRUS for the diagnosis of prostate cancer and other pelvic diseases were calculated using pathological examination results or CT enhancement results as gold standard, and the paired chi-square test was used to determine the difference between RUS and CEUS in the diagnosis of prostate cancer.Results:The accuracy, sensitivity, and specificity of RUS and CEUS in DPTRUS in the diagnosis of prostate cancer were 79.2%, 66.3%, and 93.8%, and 75.0%, 54.1%, and 95.8%, and there was no significant difference between them (χ2=3.20, P=0.063). The accuracy of ultrasonic diagnosis for other pelvic diseases was 100%, and all cases successfully underwent perineal ultrasound intervention.Conclusion:DPTRUS can correctly diagnose pelvic diseases and perform puncture biopsy for pathological diagnosis and puncture drainage treatment under the guidance of high-frequency ultrasound, thus achieving simultaneous diagnosis and treatment.

Introduction: To investigate the inhibitory effect of sorafenib combined with PEGylated resveratrol on renal cell carcinoma (RCC) and its potential mechanism. Methods: MTT assay was used to detect the inhibitory effects of PEGylated resveratrol and sorafenib alone or combination on proliferation of RCC cells. Scratch and transwell assays were performed to examine the effects on the in vitro migration and invasion of RCC cells, respectively. The anti-tumor activity as well as splenic lymphocyte proliferation of the combination therapy was evaluated in the RCC xenograft mouse model. Western blotting method was used to detect changes in proteins involved in the antitumor efficacy related signaling pathways. Results: Inhibitory effects of PEGylated resveratrol combined with sorafenib incubation on the proliferation of Renca cells was synergistically enhanced compared with the mono-incubation group (both P < 0.01, CI < 1). Scratch and transwell assays revealed that combined incubation could significantly inhibit the migration and invasion of 786-O cells in vitro. Combined PEGylated resveratrol with sorafenib could significantly inhibit the growth of Renca renal carcinoma in mice with the tumor growth inhibition (TGI) of 85.5% and one achieved complete remission on D14, while the two monotherapies were both below 43% on D14, suggesting that current combination may have synergistic anti-renal carcinoma activity. Compared with the control group, PEGylated resveratrol combined with sorafenib in vivo promoted the proliferation of unactivated splenic lymphocytes and the proliferation of lymphocytes stimulated with concanavalin A and lipopolysaccharide. Western blotting results showed that combination therapy may suppress the growth of renal cell carcinoma by inhibiting AKT/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways. Conclusion: PEGylated resveratrol combined with sorafenib can achieve synergistic anti-RCC activity, and the mechanism may be related to the inhibition of Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.

Sensorless freehand 3D ultrasound (US) reconstruction based on deep networks shows promising advantages, such as large field of view, relatively high resolution, low cost, and ease of use. However, existing methods mainly consider vanilla scan strategies with limited inter-frame variations. These methods thus are degraded on complex but routine scan sequences in clinics. In this context, we propose a novel online learning framework for freehand 3D US reconstruction under complex scan strategies with diverse scanning velocities and poses. First, we devise a motion-weighted training loss in training phase to regularize the scan variation frame-by-frame and better mitigate the negative effects of uneven inter-frame velocity. Second, we effectively drive online learning with local-to-global pseudo supervisions. It mines both the frame-level contextual consistency and the path-level similarity constraint to improve the inter-frame transformation estimation. We explore a global adversarial shape before transferring the latent anatomical prior as supervision. Third, we build a feasible differentiable reconstruction approximation to enable the end-to-end optimization of our online learning. Experimental results illustrate that our freehand 3D US reconstruction framework outperformed current methods on two large, simulated datasets and one real dataset. In addition, we applied the proposed framework to clinical scan videos to further validate its effectiveness and generalizability.

Figure 1 In the aortic short-axis view (A), the pseudo-cusp (asterisk) had a defect (arrow) which was determined as the ‘blood sack’ and its flow outlet (arrow) by simultaneous colour Doppler flow imaging. In the aortic long-axis view (B), the pseudo-cusp (asterisk) was recognized as a dissection of the non-coronary cusp belly in the setting of non-coronary cusp perforation (arrow). Biplane images (C ) helped visualize the torrential eccentric aortic regurgitation going through the ‘blood sack’ (arrow). A 3D transesophageal echocardiography reconstruction of the aortic long-axis view (D) clearly shows both the inlet (arrow) and outlet (curved arrow) of the ‘blood sack’ (asterisk). A 3D en face view of the aortic valve (E) enables a visualization of the non-coronary cusp perforation, which resembles the exact anatomy in the surgical finding (F ).